SpectraCure is a start-up company from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which are referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

SpectraCure is a start-up company from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which are referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer of the head and neck.

The need for new medical systems

Every year about 180 000 people in the US and 400 000 in the EU are diagnosed with prostate cancer. After radiotherapy, approximately 60 000 of these are affected by relapse of the cancer. The need for new treatment methods for these patients is high. Such a method is offered by interstitial PDT. Interstitial PDT has the potential to give patients significantly better quality of life than the treatment options currently offered to relapse patients.

SpectraCures focus

SpectraCure is focused on cancer treatment with medical systems containing laser light sources and reactive drugs, also called interstitial photodynamic therapy, abbreviated as PDT after “Photodynamic therapy”. The treatment method is suitable for internal solid tumours of various kinds, such as prostate, pancreas, but also in other indications such as cancer of the head and neck.

Research

The company’s technology is based on over 25 years of scientific research and work in Photodynamic therapy (PDT) combined with clinical experience of more than 2700 PDT treatments of skin tumors at Lund University Hospital.

Several research groups in Europe, the USA and Canada have conducted an active research to treat internal tumours such as prostate cancer with PDT. A couple of hundred prostate cancer patients have been treated with PDT at different university clinics, with promising results.

Treatment Benefits

SpectraCures interstitial PDT system with IDOSE® represents a whole new generation of medical devices for treatment planning and dose delivery of laser light, which enables the treatment of internal tumors. The system performs dosimetry in real time to avoid overexposure that could cause damage to healthy tissue. Underexposure that can lead to incomplete treatment is also avoided.